Equillium Inc (EQ)

Currency in USD
2.155
+0.075(+3.61%)
Real-time Data·
Earnings results expected in 3 days
EQ is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.0302.200
52 wk Range
0.2702.700
Key Statistics
Prev. Close
2.08
Open
2.09
Day's Range
2.03-2.2
52 wk Range
0.27-2.7
Volume
155.85K
Average Volume (3m)
478.63K
1-Year Change
398.8107%
Book Value / Share
0.47
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
EQ Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
6.375
Upside
+195.82%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Equillium Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy

Analyst Ratings

7 Buy
1 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 6.375
(+195.82% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Oppenheimer
Buy7.00+224.07%-New Coverage23/04/2026
B.Riley
Buy6.00+177.78%-New Coverage16/04/2026
Raymond James
Buy6.00+177.78%-New Coverage13/04/2026
Cantor Fitzgerald
Buy---New Coverage07/04/2026
Roth/MKM
Buy12.00+455.56%-New Coverage13/03/2026

Earnings

Latest Release
25/03/2026
EPS / Forecast
-0.04 / -0.07
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

EQ Income Statement

Compare EQ to Peers and Sector

Metrics to compare
EQ
Peers
Sector
Relationship
P/E Ratio
−6.0x−73.3x−0.5x
PEG Ratio
0.08−0.780.00
Price/Book
4.7x11.4x2.6x
Price / LTM Sales
-8.0x3.3x
Upside (Analyst Target)
188.5%16.7%47.7%
Fair Value Upside
Unlock−6.4%6.6%Unlock

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
4.66M7.38%9.70M
Other Institutional Investors
59.34M92.62%123.43M
Public Companies & Retail Investors
0.000.00%0.00
Total
64M100.00%133.13M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Janus Henderson Group plc9.62%6,083,23912,653
ADAR1 Capital Management, LLC8.87%5,608,07811,665

People Also Watch

2.935
OVID
+5.20%
3.23
MGNX
+3.04%
7.595
RLMD
-0.59%
4.30
CVGI
+3.61%
3.72
BATL
-0.66%

FAQ

What Is the Equillium (EQ) Stock Price Today?

The Equillium stock price today is 2.155 USD.

What Stock Exchange Does Equillium Trade On?

Equillium is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Equillium?

The stock symbol for Equillium is "EQ."

What Is the Equillium Market Cap?

As of today, Equillium market cap is 137.200M USD.

What Is Equillium's Earnings Per Share (TTM)?

The Equillium EPS (TTM) is -0.391.

When Is the Next Equillium Earnings Date?

Equillium will release its next earnings report on 07/05/2026.

From a Technical Analysis Perspective, Is EQ a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Equillium Stock Split?

Equillium has split 1 times.

How Many Employees Does Equillium Have?

Equillium has 35 employees.

What is the current trading status of Equillium (EQ)?

As of 04/05/2026, Equillium (EQ) is trading at a price of 2.155 USD, with a previous close of 2.080 USD. The stock has fluctuated within a day range of 2.030 USD to 2.200 USD, while its 52-week range spans from 0.270 USD to 2.700 USD.

What Is Equillium (EQ) Price Target According to Analysts?

The average 12-month price target for Equillium is 6.375 USD, with a high estimate of 12 USD and a low estimate of 1 USD. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +195.82% Upside potential.

What Is the EQ Premarket Price?

EQ's last pre-market stock price is 1.990 USD. The pre-market share volume is 490.000, and the stock has decreased by -0.090, or -4.330%.

What Is the EQ After Hours Price?

EQ's last after hours stock price is 2.000 USD, the stock has decreased by -0.080, or -3.850%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.